The biopharma firm projects 2026 revenue between $480M and $495M as it expands commercial teams for its topical treatment.
Arcutis Biotherapeutics announced 2026 revenue guidance of $480M to $495M, reflecting growth expectations for its flagship drug ZORYVE. The company is expanding its sales teams to support commercialization efforts for the topical treatment, which targets plaque psoriasis and atopic dermatitis.
The guidance follows a period of strategic investments in ZORYVE’s market penetration, though prior revenue prints were not disclosed. Analysts had not widely published consensus estimates for 2026, making the projection a key forward-looking indicator for investors.
Shares showed limited immediate reaction, as the guidance aligns with broader sector trends for mid-stage biopharma firms scaling commercial operations.